Sevelamer
- Generic Name
- Sevelamer
- Brand Names
- Renagel, Renvela, Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12ClNO
- CAS Number
- 52757-95-6
- Unique Ingredient Identifier
- 941N5DUU5C
Overview
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Background
Sevelamer is a phosphate binding drug used to prevent hyperphosphataemia in patients with chronic renal failure. It is marketed by Genzyme under the trade name Renagel.
Indication
For the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on hemodialysis.
Associated Conditions
- Hyperphosphataemia
Clinical Trials
FDA Approved Products
Sevelamer Carbonate
Manufacturer:ATLANTIC BIOLOGICALS CORP.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2022/09/15
NDC:17856-0921
Sevelamer Carbonate
Manufacturer:Atlantic Biologicals Corps
Route:ORAL
Strength:800 mg in 1 1
Approved: 2017/10/30
NDC:17856-0058
Sevelamer Carbonate
Manufacturer:REMEDYREPACK INC.
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/01/30
NDC:70518-3626
sevelamer carbonate
Manufacturer:Amneal Pharmaceuticals of New York LLC
Route:ORAL
Strength:800 mg in 1 1
Approved: 2020/12/31
NDC:0115-1365
Sevelamer Carbonate
Manufacturer:Winthrop U.S, a business of sanofi-aventis U.S. LLC
Route:ORAL
Strength:800 mg in 1 1
Approved: 2023/12/07
NDC:0955-1057
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath